

From: s 22
To: s 22 [SCHOFIELD, Lisa](#)
Subject: FW: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=OFFICIAL]
Date: Thursday, 2 July 2020 6:14:31 PM
Attachments: [image001.png](#)
[20200630 COVID-19 Pfizer Vx to Hunt.pdf](#)

FYI – will leave it to you on this one

From: s 47F
Sent: Tuesday, 30 June 2020 4:38 PM
To: s 22
Cc: s 47F
Subject: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=No Protective Marking]
Hi s 22

It was really good to catch up last Friday. Thanks for all your time.

As discussed, please find attached a letter from Pfizer Australia s 47F with some information about Pfizer's vaccine development in response to COVID-19.

This includes a request for a formal (virtual) engagement opportunity with members of the Vaccines Taskforce to be selected at your discretion. I am able to make senior members of Pfizer's global leadership team available for this discussion, particularly if the Minister and/or Departmental leadership can be involved. As the vaccine development landscape is moving swiftly, including through engagements with other nations, I am requesting this meeting occur at the earliest opportunity.

I am happy to discuss this matter further at any time.

Kind regards

s 47F

www.pfizer.com.au

Level 3, 500 Collins Street
Melbourne, VIC, 3000

s 47F



LEGAL NOTICE Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee(s) only. Access to this e-mail by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you are not an addressee, please inform the sender immediately. Pfizer Australia has its registered office at Level 15-18, 151 Clarence Street, Sydney, NSW, 2000